Bioavailability, Biopotency and Food Effect Study of SCD0503 Compared to Subcutaneous Regular Human Insulin
A Trial to Investigate the Relative Bioavailability, Relative Biopotency and Food Effect of SCD0503 (Oral Insulin) in Comparison to Subcutaneous Regular Human Insulin Under Euglycaemic Clamp Conditions and After Food Intake in People With Type I Diabetes
Reason for the study The participants have been diagnosed with type 1 diabetes and are being treated with standard insulin therapy.
The sponsor of the study is developing a new insulin-based medicine that can be taken by mouth (orally). For this reason, the investigational product named SCD0503 is to be tested in the study. The sponsor wants to investigate the course of blood concentrations and the blood sugar-lowering effect of the investigational product and to find out whether SCD0503 is safe.
Investigational product tested in this study The investigational product tested, SCD0503, is still under clinical evaluation and has not yet been approved for your treatment. The active ingredient is regular human insulin, which has been used for many years in approved medicines for the treatment of diabetes. SCD0503 is being used in humans for the first time in this study.
Study procedures The study will last for approximately 1 to 4 months. During this time, the participant will come to the investigational site 8 times for visits.
During 4 visits the participant will undergo a clamp examination. The blood sugar-lowering effect of the investigational product is determined using a clamp device, a computer-controlled device that maintains blood sugar at a constant level within the normal range. This is achieved by infusing a sugar solution. During 2 further visits the participant will have a meal test. During the meal test, the blood sugar-lowering effect of the investigational product is determined after intake of a standardized meal as breakfast. You will have catheters in your arms to take blood, measure your blood sugar level and to infuse glucose (sugar) or insulin, if needed.
SCD0503 is compared with a regular human insulin already approved for the treatment of diabetes.
The participant will receive SCD0503 and the comparator product during different visits to the investigational site. The participant will also receive a placebo together with the investigational or the comparator product. The placebo looks identical but contains no active ingredient. As the investigational product is administered orally and the comparator product is injected under the skin, two placebos are used in this study.
The order of medications given will be decided by chance, using a pre-defined method called randomization (a procedure similar to flipping a coin). Neither the participant nor the study physician will know which of the 2 medicines is administered at the respective dosing occasion. However, in case of emergency, this information will be quickly available.
研究概览
研究类型
注册 (估计的)
阶段
- 阶段1
联系人和位置
学习联系方式
- 姓名：Clinical Manager
- 电话号码：please reach out by email
- 邮箱：scd.global@scd.co.kr
学习地点
-
-
North Rhine-Westphalia
-
Neuss、North Rhine-Westphalia、德国、41460
- 招聘中
- Profil Institut für Stoffwechselforschung GmbH
-
接触：
- Investigator
- 电话号码：+49213140180
- 邮箱：clinicaltrialservices@profil.com
-
-
参与标准
资格标准
适合学习的年龄
- 成人
接受健康志愿者
描述
Inclusion Criteria:
- Male person with type 1 diabetes mellitus
- Age between 18 and 64 years, both inclusive
- Body Mass Index (BMI) between 18.5 and 29.9 kg/m2, both inclusive
- HbA1c ≤ 8.5%
- Fasting C-peptide <= 0.20 nmol/L
- Total insulin dose of <1.2 (I)U/kg/day
- Diabetes duration of at least 12 months at the time of screening
- Stable insulin regimen for at least 2 months prior to inclusion into the trial
Exclusion Criteria:
- Systolic blood pressure < 90 mmHg or >139 mmHg and/or diastolic blood pressure < 50 mmHg or > 89 mmHg
- Heart rate at rest outside the range of 50- 90 beats per minute
- Clinically significant abnormal standard 12-lead electrocardiogram (ECG) after 5 minutes resting in supine position at screening
- Proliferative retinopathy or maculopathy as judged by the investigator based on a recent (<1 year) ophthalmologic examination
- Peripheral neuropathy
- More than one episode of severe hypoglycaemia with seizure, coma or requiring assistance of another person during the past 6 months pior to screening
- Hospitalisation for diabetic ketoacidosis during the previous 6 months prior to screening
- Significant history of alcoholism or drug abuse
- Smoking more than 5 cigarettes or the equivalent per day
- Tested positive for hepatitis Bs antigen
- Tested positive for hepatitis C antibodies
- Positive result to the test for HIV-1/2 antibodies or HIV-1 antigen
- Estimated glomerular filtration rate (eGFR) < 60.0 mL/min/1.73m2
学习计划
研究是如何设计的？
设计细节
- 主要用途：基础科学
- 分配：随机化
- 介入模型：交叉作业
- 屏蔽：双倍的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的：Sequence 1: SCD0503 low dose-SCD0503 medium dose-Actrapid-SCD0503 high dose-SCD0503 medium -Actrapid
SCD0503 low dose: placebo B (subcutaneous injection)/ SCD0503 low dose + Placebo A medium dose (oral) SCD0503 medium dose: placebo B (subcutaneous injection)/ SCD0503 medium dose + Placebo A low dose (oral) SCD0503 high dose: placebo B (subcutaneous injection)/ SCD0503 high dose (oral) Actrapid: subcutaneous insulin/ Placebo A high dose (oral)
|
test product
其他名称：
placebo for test product
其他名称：
reference product/comparator
其他名称：
placebo for reference product
|
|
实验性的：Sequence 2: SCD0503 low dose-SCD0503 medium dose-Actrapid-SCD0503 high dose-Actrapid-SCD0503 medium
|
test product
其他名称：
placebo for test product
其他名称：
reference product/comparator
其他名称：
placebo for reference product
|
|
实验性的：Sequence 3: SCD0503 medium dose-SCD0503 high dose-SCD0503 low dose-Actrapid-SCD0503 medium-Actrapid
|
test product
其他名称：
placebo for test product
其他名称：
reference product/comparator
其他名称：
placebo for reference product
|
|
实验性的：Sequence 4: SCD0503 medium dose-SCD0503 high dose-SCD0503 low dose-Actrapid-Actrapid-SCD0503 medium
|
test product
其他名称：
placebo for test product
其他名称：
reference product/comparator
其他名称：
placebo for reference product
|
|
实验性的：Sequence 5: SCD0503 high dose-Actrapid-SCD0503 medium dose-SCD0503 low dose-SCD0503 medium-Actrapid
|
test product
其他名称：
placebo for test product
其他名称：
reference product/comparator
其他名称：
placebo for reference product
|
|
实验性的：Sequence 6: SCD0503 high dose-Actrapid-SCD0503 medium dose-SCD0503 low dose-Actrapid-SCD0503 medium
|
test product
其他名称：
placebo for test product
其他名称：
reference product/comparator
其他名称：
placebo for reference product
|
|
实验性的：Sequence 7: Actrapid-SCD0503 low dose-SCD0503 high dose-SCD0503 medium dose-SCD0503 medium-Actrapid
|
test product
其他名称：
placebo for test product
其他名称：
reference product/comparator
其他名称：
placebo for reference product
|
|
实验性的：Sequence 8: Actrapid-SCD0503 low dose-SCD0503 high dose-SCD0503 medium dose-Actrapid-SCD0503 medium
|
test product
其他名称：
placebo for test product
其他名称：
reference product/comparator
其他名称：
placebo for reference product
|
研究衡量的是什么？
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
AUCins.0-6h, area under the serum insulin concentration curve from 0 to 6 hours
大体时间：From enrollment to the end of treatment in 4 months
|
From enrollment to the end of treatment in 4 months
|
|
Cins.max, maximum observed insulin concentration
大体时间：From enrollment to the end of treatment in 4 months
|
From enrollment to the end of treatment in 4 months
|
|
AUCGIR.0-6h, area under the insulin concentration-time curve from 0 to 6 hours
大体时间：From enrollment to the end of treatment in 4 months
|
From enrollment to the end of treatment in 4 months
|
|
GRELcl, Relative biopotency (will be derived of the dose corrected ratio of AUCGIR.0-6h for oral and sc insulin)
大体时间：From enrollment to the end of treatment in 4 months
|
From enrollment to the end of treatment in 4 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
AUCins.0-1h, AUCins.0-2h, AUCins.0-4h, areas under the serum insulin concentration curve in the indicated time intervals
大体时间：From enrollment to the end of treatment in 4 months
|
From enrollment to the end of treatment in 4 months
|
|
|
tmax.ins., time to maximum observed insulin concentration
大体时间：From enrollment to the end of treatment in 4 months
|
From enrollment to the end of treatment in 4 months
|
|
|
λz, terminal elimination rate constant of insulin
大体时间：From enrollment to the end of treatment in 4 months
|
From enrollment to the end of treatment in 4 months
|
|
|
t½ is the terminal serum elimination half-life calculated as t½=ln2/λz
大体时间：From enrollment to the end of treatment in 4 months
|
From enrollment to the end of treatment in 4 months
|
|
|
MRT, Mean residence time (h)
大体时间：From enrollment to the end of treatment in 4 months
|
From enrollment to the end of treatment in 4 months
|
|
|
CL/F, Systemic clearance after oral administration (mL/min)
大体时间：From enrollment to the end of treatment in 4 months
|
From enrollment to the end of treatment in 4 months
|
|
|
V/F, volume of distribution (L)
大体时间：From enrollment to the end of treatment in 4 months
|
From enrollment to the end of treatment in 4 months
|
|
|
FRELcl, Relative bioavailability (will be derived from the dose corrected ratio of AUCins.0-6h for oral and sc insulin)
大体时间：From enrollment to the end of treatment in 4 months
|
From enrollment to the end of treatment in 4 months
|
|
|
Cins.max.fed, maximum observed insulin concentration after meal test
大体时间：From enrollment to the end of treatment in 4 months
|
From enrollment to the end of treatment in 4 months
|
|
|
AUCins.fed.0-1h, AUCins.fed.0-2h, AUCins.fed.0-4h, AUCins.fed.0-6h, areas under the serum insulin concentration curve in the indicated time intervals after meal test
大体时间：From enrollment to the end of treatment in 4 months
|
From enrollment to the end of treatment in 4 months
|
|
|
FRELfed, Relative bioavailability (will be derived of the dose corrected ratio of AUCins.fed.0-6 for oral and sc insulin)
大体时间：From enrollment to the end of treatment in 4 months
|
From enrollment to the end of treatment in 4 months
|
|
|
Food effect is investigated by comparing the total and maximum oral insulin exposure in the fasted state and after food intake
大体时间：From enrollment to the end of treatment in 4 months
|
From enrollment to the end of treatment in 4 months
|
|
|
AUCGIR.0-1h, AUCGIR.0-2h and AUCGIR.0-4h, areas under the glucose infusion rate curve in the indicated time-intervals
大体时间：From enrollment to the end of treatment in 4 months
|
From enrollment to the end of treatment in 4 months
|
|
|
GIRmax, maximum glucose infusion rate
大体时间：From enrollment to the end of treatment in 4 months
|
From enrollment to the end of treatment in 4 months
|
|
|
tmax.GIR., time to maximum glucose infusion rate
大体时间：From enrollment to the end of treatment in 4 months
|
From enrollment to the end of treatment in 4 months
|
|
|
t50%-GIR(early), time to half-maximum glucose infusion rate before GIRmax
大体时间：From enrollment to the end of treatment in 4 months
|
From enrollment to the end of treatment in 4 months
|
|
|
t50%-GIR(late), time to half-maximum glucose infusion rate after GIRmax
大体时间：From enrollment to the end of treatment in 4 months
|
From enrollment to the end of treatment in 4 months
|
|
|
Onset of action, time from trial product administration until plasma glucose concentration has decreased at least 5 mg/dL from baseline
大体时间：From enrollment to the end of treatment in 4 months
|
where baseline is defined as the mean of plasma glucose levels from -6, -4 and -2 minutes before trial product adminiadministration as measured by ClampArt
|
From enrollment to the end of treatment in 4 months
|
|
PGmax, maximum plasma glucose after meal test
大体时间：From enrollment to the end of treatment in 4 months
|
From enrollment to the end of treatment in 4 months
|
|
|
AUCPG.0-1h, AUCPG.0-2h and AUCPG.0-4h and AUCPG.0-last areas under the plasma glucose concentration curve in the indicated time-intervals
大体时间：From enrollment to the end of treatment in 4 months
|
From enrollment to the end of treatment in 4 months
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.